An Emollient PLUS Balm Is Useful for the Management of Xerosis in Patients Treated for Cancer: A Real-World, Prospective, Observational, Multicenter Study

Table 1 Demographic, clinical, and prescription characteristics of the study population at baseline

Prescriptions	N = 319
Study product frequency of application, n (%)	n = 317
Once daily	126 (39.8)
Twice daily	149 (47.0)
Thrice daily or more	42 (13.2)
Study product duration of prescription, days	n = 313
Mean (SD)	30.2 (11.6)
Other topical or systemic treatments^d, n (%)	n = 312
Yes	77 (24.7)
No	235 (75.3)

Abbreviations: N number of patients in the whole study population, n number of patients for whom data were collected, SD standard deviation. ^aCombined therapy comprised 31 patients with chemotherapy and targeted therapy; 7 patients with chemotherapy and radiotherapy; 5 patients with hormonotherapy and targeted therapy; 4 patients with chemotherapy and hormonotherapy; 3 patients with hormonotherapy and radiotherapy; 2 patients with chemotherapy, hormonotherapy, and radiotherapy; and 1 patient with chemotherapy, hormonotherapy, and targeted therapy. ^bPatients may have had xerosis on multiple parts of the body. ^cNational Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI CTCAE, version 4.0) scale for dry skin comprising three grades: grade 1 = covering < 10% of the body surface area (BSA) and no associated erythema or pruritus; grade 2 = covering 10–30% of BSA and associated erythema or pruritus, limiting instrumental activities of daily living (ADL); grade 3 = covering > 30% BSA and associated with pruritus, limiting self-care ADL. ^dPatients may have had more than one concomitant treatment